Clinical trials show that women aged 65-79 who receive estrogen alone or estrogen plus a progestin have an increased risk of cognitive impairment and dementia50, which is a indirect evidence that the feedback inhibition of FSH by estrogen supplementation in early perimenopause may be therapeutic for cognitive decline. The gene discussed is BRD2; the disease is Cognitive impairment.